Show simple item record

dc.contributor.authorDing, H
dc.contributor.authorVelasco, C
dc.contributor.authorYe, H
dc.contributor.authorLindner, T
dc.contributor.authorGrech-Sollars, M
dc.contributor.authorO'Callaghan, J
dc.contributor.authorHiley, C
dc.contributor.authorChouhan, MD
dc.contributor.authorNiendorf, T
dc.contributor.authorKoh, D-M
dc.contributor.authorPrieto, C
dc.contributor.authorAdeleke, S
dc.date.accessioned2022-02-23T09:06:41Z
dc.date.available2022-02-23T09:06:41Z
dc.date.issued2021-09-22
dc.identifier.citationCancers, 2021, 13 (19)
dc.identifier.issn2072-6694
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5028
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers13194742
dc.description.abstractMagnetic resonance imaging (MRI) has enabled non-invasive cancer diagnosis, monitoring, and management in common clinical settings. However, inadequate quantitative analyses in MRI continue to limit its full potential and these often have an impact on clinicians' judgments. Magnetic resonance fingerprinting (MRF) has recently been introduced to acquire multiple quantitative parameters simultaneously in a reasonable timeframe. Initial retrospective studies have demonstrated the feasibility of using MRF for various cancer characterizations. Further trials with larger cohorts are still needed to explore the repeatability and reproducibility of the data acquired by MRF. At the moment, technical difficulties such as undesirable processing time or lack of motion robustness are limiting further implementations of MRF in clinical oncology. This review summarises the latest findings and technology developments for the use of MRF in cancer management and suggests possible future implications of MRF in characterizing tumour heterogeneity and response assessment.
dc.formatElectronic
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleCurrent Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer.
dc.typeJournal Article
dcterms.dateAccepted2021-09-16
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/cancers13194742
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-09-22
dc.relation.isPartOfCancers
pubs.issue19
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume13
pubs.embargo.termsNo embargo
dc.contributor.icrauthorKoh, Dow-Mu


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/